(Brodalumab)Biosimilar Reference Antibody-GS40103

货号：GS40103

Brodalumab is a fully human monoclonal antibody used in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. It was first approved for medical use in 2017 and is marketed under the brand name Siliq® in the United States and Kyntheum® in the European Union. As an interleukin-17 receptor antagonist, brodalumab works by binding to and blocking the activity of a specific inflammatory pathway. While highly effective, its prescribing information includes a Boxed Warning—the most serious type of FDA warning—due to an observed risk of suicidal ideation and behavior, requiring specific risk evaluation and mitigation strategies (REMS).